Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.69 |
| ▸ | TK2 | O00142 | 5/20 | 0.63 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.59 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.59 |
| ▸ | TK1 | P04183 | 1/20 | 0.53 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286250 | 1.00 | PYGM (0.69) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL16808996 | 1.00 | PYGM (0.69) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL2577325 | 1.00 | PYGM (0.69) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL1286252 | 1.00 | PYGM (0.69) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL3671964 | 1.00 | PYGM (0.69) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL1272640 | 0.91 | TK2 (0.65) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL2583312 | 0.91 | TK2 (0.65) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL3416516 | 0.91 | TK2 (0.65) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL1272642 | 0.91 | TK2 (0.65) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL14929135 | 0.91 | DNPH1 (0.71) | PYGMTK2DNPH1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | claimed |
| EP-1756037-B1 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | claimed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | claimed |
| JP-54062327-A | — | — | None | — | — | JP | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| WO-1997006178-A1 | PYRIMIDINE NUCLEOSIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-02-20 | — | — | WO | disclosed |
| US-5215971-A | Useful for therapeutic or prophylactic control or treatment of retrovirus, especially HIV or hepatitis B | MEDIVIR AB (SE) | 1993-06-01 | — | — | US | disclosed |
| JP-S5462327-A | REMEDY FOR DNA VIRUS INFECTIOUS DISEASE | YAMASA SHOYU CO LTD | 1979-05-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PYGM 396/4885TK2 169/4885DNPH1 1101/4885 |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | PYGM 3359/4885TK2 204/4885DNPH1 1216/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | PYGM 3359/4885TK2 204/4885DNPH1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.